IMV Inc.

IMV reported a net loss of $38 million for fiscal 2022 versus a net loss of $36.6 million in 2021, an increase of $1.4 million mainly due to higher loan interest after drawing $10 million on venture debt in the second quarter. R&D expense was described as comparable to the prior year despite startup costs for two global late-stage clinical trials. In December, IMV raised $9 million, bringing cash at December 31 to $21.2 million. Management said this cash position should carry the company into the second half of 2023 and support completion of Stage 1 VITALIZE data and an early read on Stage 1 AVALON trending. No quarterly revenue, EPS, or gross margin figures were stated.

Andrew Hall emphasized that IMV believes the DPX platform is delivering on the long-promised potential of cancer vaccines, pointing to confirmed complete responses in highly refractory DLBCL and prior positive signals in bladder and ovarian cancer. He framed VITALIZE as a study meant to confirm and extend prior findings and set up a possible registration path, while stressing that full data disclosure is planned for later in the year rather than a small early readout. His tone was strongly confident about the science, but pragmatic about the financing environment and the need to explore collaboration or other strategic alternatives.

No separate CFO remarks were given on the call; Hall handled the financial discussion. He said fiscal 2022 net loss was $38 million versus $36.6 million in 2021, with the $1.4 million increase largely tied to interest from venture debt after a $10 million draw. He also said R&D was comparable year over year despite startup costs for two global late-stage studies, and that a $9 million December raise lifted cash to $21.2 million, enough to fund operations into the second half of 2023.

Analysts focused on the timing and format of upcoming data disclosures, with management saying the company is targeting full disclosure of Stage 1 VITALIZE data in the third quarter and possibly additional durability data later in the year, potentially at ASH. Questions also centered on AVALON timing, with management saying enrollment should complete around the third quarter and follow a similar presentation timeline. A second theme was the strategic review and manufacturing readiness: management said CDMO changes were made in 2022 to prepare for commercial supply, and that Stonegate was engaged to formalize exploration of collaboration or other strategic options amid limited small-cap biotech capital.